Christine Zedelmayer Sells 185,937 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 185,937 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $1.76, for a total transaction of $327,249.12. Following the completion of the sale, the chief operating officer directly owned 191,444 shares of the company’s stock, valued at $336,941.44. The trade was a 49.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Christine Zedelmayer also recently made the following trade(s):

• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The shares were sold at an average price of $1.50, for a total transaction of $150,000.00.
• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total transaction of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Price Performance

NASDAQ EQ opened at $1.92 on Wednesday. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $2.35. The firm has a market capitalization of $116.91 million, a PE ratio of -3.10 and a beta of 1.87. The company’s 50 day simple moving average is $1.41 and its 200 day simple moving average is $1.36.

Analysts Set New Price Targets

EQ has been the subject of several research reports. Wall Street Zen raised Equillium from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $1.00.

Institutional Investors Weigh In On Equillium

Several hedge funds have recently modified their holdings of the stock. Virtu Financial LLC boosted its position in shares of Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after purchasing an additional 13,591 shares during the period. State Street Corp lifted its stake in Equillium by 13.0% during the fourth quarter. State Street Corp now owns 155,420 shares of the company’s stock valued at $241,000 after buying an additional 17,900 shares in the last quarter. Persistent Asset Partners Ltd boosted its holdings in shares of Equillium by 35.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock worth $144,000 after buying an additional 24,132 shares during the period. Millennium Management LLC purchased a new position in shares of Equillium in the third quarter worth approximately $35,000. Finally, Geode Capital Management LLC increased its position in shares of Equillium by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 345,310 shares of the company’s stock worth $535,000 after acquiring an additional 34,491 shares in the last quarter. 27.05% of the stock is owned by hedge funds and other institutional investors.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.